Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
11/06/2026 15:48
BRIEF-Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination June 11 (Reuters) - Genmab A/S GMAB.CO:
PRESENTS EPCORE FL-1 SUBGROUP DATA DEMONSTRATING CONSISTENT EFFICACY AND SAFETY RESULTS FOR EPCORITAMAB IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (R2) ACROSS RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) PATIENTS
EPCORITAMAB WITH RITUXIMAB AND LENALIDOMIDE SHOWS SUSTAINED EFFICACY AND MANAGEABLE SAFETY
Source text: ID:nBw4KyhV7a
Further company coverage: GMAB.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss